Novel metal-based photosensitizers for photodynamic therapy: exploratory study (Conference Presentation)

Lindsey Carlsen; Taylor Mandeville; Patrick Barrett; Evan Bradner; Tariq Sainuddin; Sherri McFarland; Sarah Chamberlain; David Bellnier; Gal Shafirstein

doi:10.1117/12.2526180

14 August 2019 Novel metal-based photosensitizers for photodynamic therapy: exploratory study (Conference Presentation)

Lindsey Carlsen, Taylor Mandeville, Patrick Barrett, Evan Bradner, Tariq Sainuddin, Sherri McFarland, Sarah Chamberlain, David Bellnier, Gal Shafirstein

Author Affiliations +

Proceedings Volume 11070, 17th International Photodynamic Association World Congress; 110701U (2019) https://doi.org/10.1117/12.2526180
Event: 17th International Photodynamic Association World Congress, 2019, Cambridge, Massachusetts, United States

Abstract

Ruthenium and osmium-based photosensitizers (PS) are compounds of interest for use in photodynamic therapy (PDT). These PS’s can be activated by light wavelengths in the range of 400-675 nm, which can be selected based on the tumor environment, treatment area, and available light sources. The objective of this study was to explore these PS’s for the treatment of several relatively aggressive cancer cell lines. A human adenocarcinoma cell line (A549) was treated with ruthenium-based compounds at concentrations of 1, 5, or 10 uM, followed by light treatment of 93 J/cm2 at either 532 nm or 630 nm. Similarly, osmium-based compounds were used to treat A549, murine melanoma (B16F10) and squamous cell carcinoma (SCCVII) cell lines at concentrations of 0.05, 1, or 3 uM, followed by light treatment of 93 J/cm2 at 630 nm. Cells survival was assessed 24 hours after PDT treatment using either alamarBlue or MTT cell viability assays. In-vitro MTT viability assays revealed that ruthenium-based compounds activated with 630 nm light showed high SCCVII cell toxicity at 5uM. AlamarBlue assays have shown that ruthenium based compounds activated by 532 nm light show high A549 cell toxicity at 1uM in-vitro. Osmium-based compounds showed optimal PDT-mediated cytotoxicity in SCCVII, A549, and B16F10 cell lines at a concentration of 1uM activated by 630 nm light, while exhibiting minimal dark toxicity. The Ruthenium and Osmium-based compounds are potentially potent PSs against lung, melanoma and squamous cell carcinoma cells, in-vitro.

Conference Presentation

Citation Download Citation

Lindsey Carlsen, Taylor Mandeville, Patrick Barrett, Evan Bradner, Tariq Sainuddin, Sherri McFarland, Sarah Chamberlain, David Bellnier, and Gal Shafirstein "Novel metal-based photosensitizers for photodynamic therapy: exploratory study (Conference Presentation)", Proc. SPIE 11070, 17th International Photodynamic Association World Congress, 110701U (14 August 2019); https://doi.org/10.1117/12.2526180

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
PRESENTATION

WATCH
PRESENTATION SAVE TO MY LIBRARY

GET CITATION

KEYWORDS

Photodynamic therapy

In vitro testing

Ruthenium

Toxicity

Melanoma

Cancer

Light

Show All Keywords

Keywords/Phrases

Search In:

Publication Years